Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 03-28 12:23:26 EDT

0.8521

-0.0295

-3.35%

High0.8884	Low0.8436	Vol302.88K
Open0.8800	D1 Closing0.8816	Amplitude5.08%
Mkt Cap97.65M	Tradable Cap85.07M	Total Shares114.60M
T/O260.71K	T/O Rate0.30%	Tradable Shares99.83M
P/B0.31	ROE-54.21%	EPS-1.64
52wk High7.65	52wk Low0.8333	P/E-0.52
Dividend0.00	Div.Yield0.00	ROA-25.81%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":0.8521,"timestamp":1743178840769,"preClose":0.8816,"halted":0,"volume":302884,"delay":0,"floatShares":99833025,"shares":114597425,"eps":-1.639999,"marketStatus":"Trading","change":-0.0295,"latestTime":"03-28 12:23:26 EDT","open":0.88,"high":0.8884,"low":0.8436,"amount":260711.46164559998,"amplitude":0.050817,"askPrice":0.8558,"askSize":2600,"bidPrice":0.8482,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.639999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":0.8816,"postHourTrading":{"tag":"盘后","latestPrice":0.8773,"preClose":0.8816,"latestTime":"19:55 EDT","volume":20921,"amount":18443.4161,"timestamp":1743119749872},"volumeRatio":0.491465,"impliedVol":6.1694,"impliedVolPercentile":0.984},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2517449661","title":"Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2517449661","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517449661?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 20:46","pubTimestamp":1741438015,"startTime":"0","endTime":"0","summary":"Last week, you might have seen that Fate Therapeutics, Inc.  released its full-year result to the market. The early response was not positive, with shares down 9.8% to US$1.01 in the past week. Fate Therapeutics reported revenues of US$14m, in line with expectations, but it unfortunately also reported  losses of US$1.64 per share, which were slightly larger than expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-inc-nasdaq-fate-124655083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ",".IXIC","FATE"],"gpt_icon":0},{"id":"2517127615","title":"Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2517127615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517127615?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 14:01","pubTimestamp":1741327292,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Economy & Political Environment category. Fate Therapeutics Inc. faces significant ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-inc-faces-global-expansion-challenges-amid-political-and-economic-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-inc-faces-global-expansion-challenges-amid-political-and-economic-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2517937671","title":"Wedbush Remains a Hold on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517937671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517937671?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 01:28","pubTimestamp":1741282113,"startTime":"0","endTime":"0","summary":"In a report released today, David Nierengarten from Wedbush maintained a Hold rating on Fate Therapeutics (FATE – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-hold-on-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-hold-on-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2517193749","title":"Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193749","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517193749?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 01:26","pubTimestamp":1741281978,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-optimism-hold-rating-for-fate-therapeutics-amid-early-stage-progress-and-market-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-optimism-hold-rating-for-fate-therapeutics-amid-early-stage-progress-and-market-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","FATE","SSI"],"gpt_icon":0},{"id":"2517319372","title":"Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517319372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517319372?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 01:20","pubTimestamp":1741281636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE – Research Report), ALX Onco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX","BK4139","ALXO","BK4137","ALX","BK4231","HCSG","FATE","BK4007","BK4080"],"gpt_icon":0},{"id":"2517164560","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE) and Stevanato Group (STVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517164560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517164560?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 23:20","pubTimestamp":1741274418,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report) and Ste...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-and-stevanato-group-stvn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-and-stevanato-group-stvn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["STVN","BK4139","BK4121","BK4137","FATE","BK4539","HCSG"],"gpt_icon":0},{"id":"2517316389","title":"Fate Therapeutics Price Target Maintained With a $5.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2517316389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517316389?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:20","pubTimestamp":1741270800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 09:20 ET (14:20 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"gpt_icon":0},{"id":"2517163869","title":"Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517163869?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:10","pubTimestamp":1741270200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 09:10 ET (14:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791807156.HKD","LU2361044949.HKD","LU0477156953.USD","IE00B7SZLL34.SGD","LU0052756011.USD","LU1506573853.SGD","FATE","IE0002270589.USD","LU0211327993.USD","LU0208291251.USD","LU0070302665.USD","BK4504","LU0048573561.USD","LU0708994859.HKD","LU0149725797.USD","LU0417517546.SGD","LU0072461881.USD","LU1035773651.USD","LU0128525929.USD","LU0310800379.SGD","LU2236285917.USD","LU0648001328.SGD","LU0162691827.USD","LU0310800965.SGD","LU0683600562.USD","LU1201861249.SGD","LU1267930573.SGD","BK4585","LU0106831901.USD","BK4501","LU0251131958.USD","LU0742534661.SGD","LU0640476718.USD","IE00B19Z3581.USD","LU0971096721.USD","LU0314106906.USD","LU0320765489.SGD","BK4559","BK4139","LU1074936037.SGD","LU2361044865.SGD","LU2361045086.USD","LU0251142724.SGD","LU0130517989.USD","LU0310799852.SGD","LU0128525689.USD","LU0211328371.USD","LU1069347547.HKD","LU0289960550.SGD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2517571167","title":"FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2517571167","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517571167?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:04","pubTimestamp":1741269840,"startTime":"0","endTime":"0","summary":"Fate Therapeutics FATE reported a loss of 31 cents per share  in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 44 cents. The company reported a loss of 45 cents per share in the year-ago period.Including the impairment loss of $14.7 million, loss per share was 44 cents.The company earned collaboration revenues of $1.9 million, surpassing the Zacks Consensus Estimate of $1 million. The figure also increased from $1.7 million reported in the year-ago quarter.Revenues were derived from preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen under its collaboration with Ono Pharmaceutical.Cash, cash equivalents and investments as of Dec. 31, 2024, totaled $306.7 million. Fate expects the current cash balance to sustain an operating runway through 2026.FATE also amended the clinical protocol of its phase I autoimmunity study on FT819 to include a new treatment arm to assess the safety, pharmac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-q4-earnings-beat-autoimmunity-140400712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPHLF","OPHLY","FATE"],"gpt_icon":0},{"id":"2517156999","title":"Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156999?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 19:58","pubTimestamp":1741262333,"startTime":"0","endTime":"0","summary":"In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Hold rating on Fate Therapeutics (FATE – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-hold-rating-for-fate-therapeutics-fate-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-hold-rating-for-fate-therapeutics-fate-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","FATE"],"gpt_icon":0},{"id":"2517156902","title":"Hold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156902?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 19:57","pubTimestamp":1741262233,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating today. Gil Blum has given his Hold rating due to a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/hold-rating-for-fate-therapeutics-amid-early-stage-pipeline-uncertainty-and-cautious-cash-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/hold-rating-for-fate-therapeutics-amid-early-stage-pipeline-uncertainty-and-cautious-cash-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","FATE"],"gpt_icon":0},{"id":"2517992156","title":"Fate Therapeutics price target lowered to $3 from $5 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2517992156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517992156?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 19:55","pubTimestamp":1741262150,"startTime":"0","endTime":"0","summary":"Stifel lowered the firm’s price target on Fate Therapeutics (FATE) to $3 from $5 and keeps a Hold rating on the shares. Key updates the firm will b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-price-target-lowered-to-3-from-5-at-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-price-target-lowered-to-3-from-5-at-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","FATE"],"gpt_icon":0},{"id":"2517130576","title":"Barclays Keeps Their Buy Rating on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517130576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517130576?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 18:31","pubTimestamp":1741257096,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson maintained a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a price target of $10.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"gpt_icon":0},{"id":"2517613054","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517613054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517613054?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 18:30","pubTimestamp":1741257042,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research Report), Organon (OGN – Resear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-organon-ogn-and-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-organon-ogn-and-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","BK4139","BK4588","FATE","BK4137","GPCR","BK4599","BK4559","LU2065169927.USD","LU2065171402.SGD","OGN","LU2065171311.SGD","HCSG","LU2065170008.USD"],"gpt_icon":0},{"id":"2517547130","title":"Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2517547130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517547130?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 18:30","pubTimestamp":1741257007,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Hold rating on Fate Therapeutics (FATE – Research Report) yesterday and set a price target of $4.00. Yan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-fate-therapeutics-amid-ft819-program-developments-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-fate-therapeutics-amid-ft819-program-developments-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139","LU0251131958.USD","LU1668664300.SGD","LU1791807156.HKD","LU0070302665.USD","BK4207","BK4588","LU0162691827.USD","LU0208291251.USD","LU0106831901.USD","LU0477156953.USD","LU0742534661.SGD","LU2236285917.USD","LU0310799852.SGD","IE00B19Z3581.USD","BK4504","LU0417517546.SGD","LU2361044949.HKD","LU1201861249.SGD","LU0072461881.USD","LU0320765489.SGD","LU1267930573.SGD","LU0708994859.HKD","BK4559","LU0130517989.USD","LU1074936037.SGD","LU1814569148.SGD","LU0029864427.USD","LU0267386448.USD","LU0314106906.USD","LU0052756011.USD","LU0211327993.USD","LU1363072403.SGD","IE0002270589.USD","BK4585","LU0211328371.USD","LU0980610538.SGD","LU0971096721.USD","LU0251142724.SGD","LU1267930227.SGD","IE00B7SZLL34.SGD","LU0149725797.USD","LU2361045086.USD","LU0128525929.USD","LU0130102774.USD","LU0128525689.USD","LU0648001328.SGD","LU0256863811.USD","LU0310800379.SGD"],"gpt_icon":0},{"id":"2517975723","title":"Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975723","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975723?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 06:10","pubTimestamp":1741212603,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 29.55%. A quarter ago, it was expected that this clinical-stage biotech company that develops stem cell treatments would post a loss of $0.42 per share when it actually produced a loss of $0.40, delivering a surprise of 4.76%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Fate Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.86 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 46.46%. This compares to year-ago revenues of $1.68 million. The company has topped consensus revenue estimates four times over the last four quarters.Fate Therapeutics shares have lost about 4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-fate-reports-q4-221003223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FATE"],"gpt_icon":0},{"id":"2517858924","title":"Fate Therapeutics: Q4 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2517858924","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517858924?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:12","pubTimestamp":1741209143,"startTime":"0","endTime":"0","summary":"SAN DIEGO  — SAN DIEGO  — Fate Therapeutics Inc.  on Wednesday reported a loss of $52.2 million in its fourth quarter.On a per-share basis, the San Diego-based company said it had a loss of 44 cents. Losses, adjusted for asset impairment costs, came to 31 cents per share.The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 44 cents per share.The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $1.3 million.For the year, the company reported a loss of $186.3 million, or $1.64 per share. Revenue was reported as $13.6 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-q4-earnings-snapshot-211223519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FATE"],"gpt_icon":0},{"id":"2517921797","title":"Fate Therapeutics reports Q4 EPS (44c), consensus (42c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921797?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:05","pubTimestamp":1741208759,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $1.86M, consensus $1.57M. “We begin 2025 with resolve and focus to advance our lead clinical programs in autoimmunity and oncolo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-reports-q4-eps-44c-consensus-42c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-reports-q4-eps-44c-consensus-42c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"gpt_icon":0},{"id":"2517921597","title":"Fate Therapeutics Q4 2024 GAAP EPS $(0.44) Misses $(0.43) Estimate, Sales $1.860 Miss $1.416M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921597","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921597?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:02","pubTimestamp":1741208564,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 2.22 percent increase over losses of $(0.45) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44151534/fate-therapeutics-q4-2024-gaap-eps-0-44-misses-0-43-estimate-sales-1-860-miss-1-416m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Fate Therapeutics Q4 2024 GAAP EPS $(0.44) Misses $(0.43) Estimate, Sales $1.860 Miss $1.416M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"gpt_icon":0},{"id":"2517929259","title":"Fate Therapeutics Q4 Operating Expenses USD 63.608 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517929259?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nPLXD9CAF5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0588},{"period":"1month","weight":-0.2833},{"period":"3month","weight":-0.4524},{"period":"6month","weight":-0.7531},{"period":"1year","weight":-0.8799},{"period":"ytd","weight":-0.4657}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.03599},{"month":2,"riseRate":0.583333,"avgChangeRate":0.064289},{"month":3,"riseRate":0.5,"avgChangeRate":0.00028},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.055265},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.016902},{"month":6,"riseRate":0.545455,"avgChangeRate":0.010259},{"month":7,"riseRate":0.454545,"avgChangeRate":0.056385},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.021881},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.018445},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.106424},{"month":11,"riseRate":0.583333,"avgChangeRate":0.111361},{"month":12,"riseRate":0.583333,"avgChangeRate":0.060305}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction